You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

44 Items
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative
May 2019
Cancer Type: Genitourinary, Prostate     
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
    triptorelin
ODB - General Benefit
    bicalutamide
Jan 2018
Cancer Type: Genitourinary, Renal cell / Kidney     
Intent: Palliative
Drugs Used:
Aug 2019
Cancer Type: Gynecologic, Cervix     
Intent: Palliative
Drugs Used:
topotecan (Unfunded),
May 2019
Cancer Type: Sarcoma, Ewing's, Soft Tissue     
Intent: Palliative
Feb 2018
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Apr 2016
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Fludarabine - Indolent Lymphoma
Apr 2016
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Funding:
ODB Limited Use
    fludarabine - For second-line therapy of patients with CLL who have failed or are intolerant to chlorambucil (tablets)
ODB - General Benefit
    cyclophosphamide - oral tablets
Jun 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
Jun 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    cyclophosphamide - oral tablets
May 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
New Drug Funding Program
    Rituximab in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (SC) in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (SC) - Retreatment - Indolent Lymphoma
Oct 2018
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab - Previously Untreated Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab - Second Line - Chronic Lymphocytic Leukemia
ODB Limited Use
    fludarabine - For the first-line treatment of CLL in combination with rituximab (tablets; with or without cyclophosphamide)
ODB Limited Use
    fludarabine - For second-line therapy of patients with CLL who have failed or are intolerant to chlorambucil (tablets)
New Drug Funding Program
    Rituximab (SC) - Previously Untreated Chronic Lymphocytic Leukemia
Jun 2019